| Biomarker ID | 1622 |
| PMID | 31035590 |
| Year | 2019 |
| Biomarker | VEGFR2 [SNP: rs2034967; C Vs T] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.45 (95% CI: 0.28–0.72) |
| Effect on Pathways | Pathway include: Apoptotic Pathways in Synovial Fibroblasts; GPCR Pathway; ERK Signaling; Nanog in Mammalian ESC Pluripotency; CREB Pathway |
| Experiment | Overall Survival Vs No Overall Survival |
| Type of Biomarker | Prognostic |
| Cohort | 418 patients in the training cohort (76 died) and 131 patients in the validation cohort (25 died) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.00000008 |
| Method Used | Allele specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |